April 2010

Rheonix, Inc. Completes $12.6 Million Series A Financing

Ithaca, NY — April 21, 2010 — Rheonix, Inc. today announced the completion of a $12.6 million Series A financing to continue development of the Rheonix CARD™ (Chemistry And Reagent Device) system. This powerful, analytic platform for the lifescience industry vertically integrates all the functions of traditional molecular diagnostic instrumentation into a single system to achieve unprecedented raw sample preparation, molecular amplification and multiplex analysis. The Rheonix CARD system provides… Read More »

National Institutes of Health Renews Partnership with Rheonix and Awards Additional Grant to Develop CARD™ Technology for Simultaneous Detection of Multiple Sexually Transmitted Infectious Agents

Ithaca, N.Y. — April 16, 2010 — Rheonix, Inc. today announced that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), continues to support its Point-of-Care Partnership with Rheonix for a second year. As part of the grant, Rheonix will receive an additional $396,775 award to optimize its CARD™ (Chemistry And Reagent Device) diagnostic platform for simultaneous, multiplex, point-ofcare detection of the… Read More »
Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More